ICCM News & Events

Reports Q1 revenue $911K, consensus $1.34M. "We are off to an incredibly strong start to 2026 and we are highly encouraged by the growing momentum we are experiencing in the U.S. for ProSense in early-stage breast cancer, which has been building over time through our clinical data, physician engagement, and regulatory milestones," said CEO Eyal Shamir. "Our commercial team is building a strong pipeline of hospitals and clinics, many of which are progressing through their internal purchasing processes, and we are now seeing that pipeline converting into revenue...We plan to leverage this rising interest and expand our U.S. sales footprint this year to eight regions, supporting the increasing demand from our marketing efforts and heightened positive response to our presence at key recent industry conferences... ProSense integrates seamlessly into existing clinical workflows without requiring additional infrastructure, so we believe we are well positioned to scale. We also expect our ChoICE post-marketing study, which will include 30 U.S. sites and where both commercial and clinical procedures will be performed, will further accelerate adoption and broaden access to ProSense across the U.S."

IceCure Medical files to sell 16M ordinary share for holders

IceCure Medical announced that it has entered into securities purchase agreements with healthcare focused institutional investors for the purchase and sale of 8M ordinary shares at a purchase price of 50c per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $4M, before deducting placement agent fees and other offering expenses. In addition, in a concurrent private placement, IceCure will issue and sell unregistered Series B warrants to purchase up to 8M ordinary shares and Series C warrants to purchase up to 8M ordinary shares. The Warrants will have an exercise price of 55c per share and will be exercisable immediately upon issuance. The Series B Warrants will expire five years following the date of issuance and the Series C Warrants will expire one year following the date of issuance. The closing of the offering is expected to occur on or about March 27, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.